NCT02765685

Brief Summary

This is a biomedical study on a medical device. 120 patients will participate in this study and will be split into 2 groups:

  • 60 patients in the "usual care" group: these patients will receive the usual care proposed by their doctor for 12 months.
  • 60 patients in the "ODRA" group: these patients will wear the ODRA brace for 12 months in addition to their usual care. They will be instructed to wear the brace for at least 6 hours per day, 5 days per week and to take it off during rest periods when lying down. The distribution of patients in the groups will be randomized. For this study, patients will be followed for 12 months, spread over 3 visits: inclusion visit, follow-up visit at 6 months and 12 months.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P75+ for not_applicable knee-osteoarthritis

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2015

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

April 29, 2016

Completed
10 days until next milestone

First Posted

Study publicly available on registry

May 9, 2016

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2017

Completed
Last Updated

August 22, 2018

Status Verified

August 1, 2018

Enrollment Period

2.4 years

First QC Date

April 29, 2016

Last Update Submit

August 20, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Pain measured using a VAS (visual analogue scale) by the patient

    12 months

Secondary Outcomes (8)

  • Ratio differential cost-utility

    12 months

  • Evolution of pain measured by VAS in the form of a self-questionnaire

    6 months

  • Evolution of the Function score- Everyday life of the KOOS (Knee injury and osteoarthritis outcome score) self-questionnaire

    12 months

  • Evolution of quality of life measured by the AMIQUAL self-questionnaire

    12 months

  • Evolution de overall disease activity measured by VAS

    12 months

  • +3 more secondary outcomes

Study Arms (2)

ODRA

EXPERIMENTAL
Device: brace ODRA (PROTEOR company)Other: Usual care

usual care

ACTIVE COMPARATOR
Other: Usual care

Interventions

Port of the orthosis ODRA during day during 12 months, Complement to their usual care. The subjects will have for instruction to wear the brace a minimum of 6 hours a day, 5 days a week, And to remove it during the rest periods in lengthened position.

ODRA

The patients will benefit only from the coverage proposed usually, by their regular doctor and according to the notices of the medical and paramedical specialists taking care of this pathology (physiotherapists, orthopaedic osteopaths, sports medicine physician, surgeon, rheumatologists, rehabilitative doctors, etc.). In the absence of recommendations on the modalities of coverage of the gonarthrose and in front of diverse clinical habits, the "usual" said coverage can be at the same time medicinal (anti-inflammatory, painkilling, …), non-medicinal (physiotherapy, port of an orthosis, …), even surgical, according to the influencers.

ODRAusual care

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18
  • Knee osteoarthritis (defined according to American College of Reumatology criteria):
  • radiological stage II, III or IV according to the Kellgren and Lawrence (KL) classification documented by a radiological examination in the previous 12 months.
  • Predominantly affecting the internal compartment (internal KL stage greater than external KL stage) and symptomatic with a Pain Visual Analogue Scale \> 40/100 on the target side (side with the most symptomatic disease)
  • Patients who have provided written consent
  • Patients able to understand simple instructions, to read, write, and to give informed consent
  • Patients with national health insurance cover

You may not qualify if:

  • Severe venous insufficiency in the lower limbs
  • History of deep venous thrombosis in the lower limbs
  • Inflammatory flare of knee osteoarthritis (synovial effusion) on the target side
  • Person over 18 under guardianship or unable to provide consent
  • Pregnant or breast-feeding women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU Dijon Bourgogne

Dijon, 21079, France

Location

MeSH Terms

Conditions

Osteoarthritis, Knee

Condition Hierarchy (Ancestors)

OsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 29, 2016

First Posted

May 9, 2016

Study Start

February 1, 2015

Primary Completion

July 1, 2017

Last Updated

August 22, 2018

Record last verified: 2018-08

Locations